Meiji Seika Pharma wins EU orphan drug status for morcamilast in palmoplantar pustulosis
EU orphan status for morcamilast in PPP reshapes Meiji Seika Pharma’s European strategy. See what it means for PDE4 competition and rare dermatology.
EU orphan status for morcamilast in PPP reshapes Meiji Seika Pharma’s European strategy. See what it means for PDE4 competition and rare dermatology.